Elicio Therapeutics Inc. (ELTX) — Cash Flow-to-Debt Ratio
Elicio Therapeutics Inc. (ELTX) has a Cash Flow-to-Debt Ratio of -0.48x as of March 2026, meaning its operating cash flow of $-11.64 Million could theoretically repay 0% of its total liabilities ($24.13 Million) in one year. Check ELTX capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Elicio Therapeutics Inc. Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Elicio Therapeutics Inc. across 10 annual periods. Also explore Elicio Therapeutics Inc. assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Elicio Therapeutics Inc. (2012–2025)
Year-by-year debt coverage analysis for Elicio Therapeutics Inc.. For market capitalisation and broader financial context, see ELTX market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.53x | $-36.95 Million | $24.23 Million | ▼ -62.5% |
| 2024 | -0.94x | $-37.07 Million | $39.49 Million | ▲ +54.7% |
| 2023 | -2.07x | $-32.69 Million | $15.77 Million | ▼ -28.5% |
| 2022 | -1.61x | $-22.18 Million | $13.75 Million | ▼ -1.1% |
| 2021 | -1.60x | $-23.94 Million | $15.01 Million | ▼ -860.4% |
| 2020 | -0.17x | $-22.89 Million | $137.80 Million | ▲ +79.4% |
| 2019 | -0.81x | $-24.59 Million | $30.47 Million | ▲ +22.4% |
| 2018 | -1.04x | $-8.02 Million | $7.72 Million | ▼ -462.7% |
| 2013 | 0.29x | $1.89 Million | $6.60 Million | ▲ +82.7% |
| 2012 | 0.16x | $1.07 Million | $6.79 Million | — |